ReviewCellular & molecular biology letters2012
Influence of dendrimers on red blood cells.
Review in Cellular & molecular biology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 69 citations in OpenAlex.
- Nanoformulated Phytochemicals Against Pancreatic Cancer: Emerging Advances in Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models.International journal of molecular sciences · 2025Review
- From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications.Pharmaceutics · 2025Review
- Molecular Mechanisms of Action of Dendrimers with Antibacterial Activities on Model Lipid Membranes.Polymers · 2025Article
- Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells.Oncology research · 2025Review
- In Vitro Interactions of Amphiphilic Phosphorous Dendrons with Liposomes and Exosomes-Implications for Blood Viscosity Changes.Pharmaceutics · 2022Article
- Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma.Frontiers in oncology · 2022Review
- Blood Compatibility of Amphiphilic Phosphorous Dendrons-Prospective Drug Nanocarriers.Biomedicines · 2021Article
- Molecularly targeted nanoparticles: an emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease.Cellular & molecular biology letters · 2021Article
- A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus.Journal of medical virology · 2020Article
- Immunotoxicity Considerations for Next Generation Cancer Nanomedicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.Biomolecules · 2019Article
- Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.Advanced drug delivery reviews · 2019Review
- In vitro toxicity studies of biodegradable, polyelectrolyte nanocapsules.International journal of nanomedicine · 2018Article
- PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.Advanced drug delivery reviews · 2016Review
- Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- In Vivo Nanodetoxication for Acute Uranium Exposure.Molecules (Basel, Switzerland) · 2015Article
- A study on the hemocompatibility of dendronized chitosan derivatives in red blood cells.Drug design, development and therapy · 2015Article
- The influence of heterocyclic compound-PAMAM dendrimer complexes on evoked electrical responses in slices of hypoxic brain tissue.Cellular & molecular biology letters · 2014Article
- Nanodrugs: pharmacokinetics and safety.International journal of nanomedicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendrimers, highly branched macromolecules with a specific size and shape, provide many exciting opportunities for biomedical applications. However, most dendrimers demonstrate toxic and haemolytic activity because of their positively charged surface. Masking the peripheral cationic groups by coating them with biocompatible molecules is a method to reduce it. It was proven that modified dendrimers can even diminish haemolytic activity of encapsulated drugs. Experiments confirmed that anionic dendrimers are less haemotoxic than cationic ones. Due to the high affinity of dendrimers for serum proteins, presence of these components in an incubation buffer might also influence red blood cell (RBC)-dendrimer interactions and decrease the haemolysis level. Generally, haemotoxicity of dendrimers is concentration-, generation-, and time-dependent. Various changes in the RBCs' shape in response to interactions with dendrimers have been observed, from echinocytic transformations through cell aggregation to cluster formation, depending on the dendrimer's type and concentration. Understanding the physical and chemical origins of dendrimers' influences on RBCs might advance scientists' ability to construct dendrimers more suitable for medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.